Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma
H. Chen (South San Francisco, United States of America), R. Kunder (South San Francisco, United States of America), Y. Zou (South San Francisco, United States of America), H. Gugelmann (South San Francisco, United States of America), J. Galanter (South San Francisco, United States of America), R. Zhu (South San Francisco, United States of America), R. Owen (South San Francisco, United States of America), T. Staton (South San Francisco, United States of America), M. Wright (South San Francisco, United States of America), M. Durk (South San Francisco, United States of America), A. Eliahu (South San Francisco, United States of America), M. Wilson (South San Francisco, United States of America), R. Beasley (Wellington, New Zealand), I. Braithwaite (Wellington, New Zealand)
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Chen (South San Francisco, United States of America), R. Kunder (South San Francisco, United States of America), Y. Zou (South San Francisco, United States of America), H. Gugelmann (South San Francisco, United States of America), J. Galanter (South San Francisco, United States of America), R. Zhu (South San Francisco, United States of America), R. Owen (South San Francisco, United States of America), T. Staton (South San Francisco, United States of America), M. Wright (South San Francisco, United States of America), M. Durk (South San Francisco, United States of America), A. Eliahu (South San Francisco, United States of America), M. Wilson (South San Francisco, United States of America), R. Beasley (Wellington, New Zealand), I. Braithwaite (Wellington, New Zealand). Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma. 1196
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
High levels of fractional exhaled nitric oxide (FeNO) in severe oral steroid-dependent asthma are associated with eosinophilia and atopy Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009
Effect of adding montelukast to budesonide treatment on exhaled nitric oxide in mild to moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 259s Year: 2004
Endothelin -1 in exhaled breath condensate during omalizumab therapy in patients with severe persistent allergic asthma Source: Annual Congress 2009 - Airway inflammation and asthma control Year: 2009
Exhaled nitric oxide and bronchial hyperresponsiveness in patients with cough variant asthma or new-onset classic mild asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Inhaled corticosteroids decrease exercise-induced inflammation in patients with COPD Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease Year: 2007
Stability of exhaled nitric oxide (FE NO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008
Effect of montelukast treatment and withdrawal on exhaled nitric oxide and lung function in atopic asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007
Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels Source: International Congress 2017 – Monitoring asthma control Year: 2017
Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children Source: Eur Respir J 2002; 20: 630-634 Year: 2002
Effects of roflumilast on exhaled NO, airway hyperresponsiveness, and inflammatory markers in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma Source: Eur Respir J 2010; 35: 1221-1227 Year: 2010
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Induced sputum in children with mild-moderate persistent asthma: the effect of inhaled corticosteroid treatment Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008
Are exhaled nitric oxide and airway hyperresponsiveness good predictive markers of inhaled corticosteroids dose reduction failures in children? Source: Annual Congress 2003 - Role of exhaled NO in diagnosis and therapy of childhood asthma Year: 2003
Effect of formoterol with or without budesonide in repeated low-dose allergen challenge Source: Eur Respir J 2009; 33: 747-753 Year: 2009
Exhaled nitric oxide (FeNO), sputum analysis and asthma control score in children with mild to moderate asthma Source: Annual Congress 2008 - Assessment of inflammation, hyperresponsiveness and response to exercise in asthmatic children Year: 2008
Non-adherence to inhaled corticosteroid therapy as an explanation for persistently elevated exhaled nitric oxide levels in patients with asthma: Effect of directly observed therapy with inhaled corticosteroids (DOT-ICS) Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
The relationship between exhaled nitric oxide and compliance/adherence in patients with bronchial asthma using inhaled corticosteroids Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012
Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study Source: Eur Respir J 2006 Oct 01;28(4):748-755 Year: 2006